(Q37831972)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

When to initiate and discontinue biologic treatments for rheumatoid arthritis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Katerina Chatzidionysiou

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

R F van Vollenhoven

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

23 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

614-625

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261760%20AND%20SRC:MED&resulttype=core&format=json

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2011.02355.X